Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Absence Seizures Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT04666610
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 25 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452
View directory record Official record
Conditions
Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions
Ethosuximide, Lamotrigine, Valproic acid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
30 Months to 13 Years
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT05109234
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years to 26 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 21, 2026, 11:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study

NCT00041951
View directory record Official record
Conditions
Childhood Absence Epilepsy, Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
3 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2016 · Synced Jul 21, 2026, 11:23 AM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

NCT06425159
View directory record Official record
Conditions
Generalized Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 21, 2026, 11:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Comorbidities in Epilepsy Using Eye Movement Recordings

NCT06310772
View directory record Official record
Conditions
Childhood Absence Epilepsy, Absence Seizures, Epilepsy Comorbidities
Interventions
Not listed
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Orange, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 11:23 AM EDT
Completed No phase listed Observational

Magnetoencephalography in Absence Seizures

NCT00884351
View directory record Official record
Conditions
Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
7 Years to 35 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 11:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Why Are Patients With Absence Seizures Absent? A Brain Imaging Study

NCT00393666
View directory record Official record
Conditions
Childhood Absence Epilepsy
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
6 Years to 18 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Jul 21, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

NCT03355300
View directory record Official record
Conditions
Childhood Absence Epilepsy
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Epidiolex in Typical Absence Seizures

NCT04899050
View directory record Official record
Conditions
Study the Efficacy of Epidiolex for Typical Absence Seizures
Interventions
Cannabidiol (Epidiolex)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
6 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Jul 21, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322
View directory record Official record
Conditions
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Interventions
Brivaracetam Film-coated tablet, Brivaracetam oral solution
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
2 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Birmingham, Alabama • Orange, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures

NCT00144872
View directory record Official record
Conditions
Seizure, Absence
Interventions
Lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
San Jose, California • Loxahatchee Groves, Florida • Melbourne, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Jul 21, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

NCT03336242
View directory record Official record
Conditions
Childhood Absence Epilepsy
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jul 21, 2026, 11:23 AM EDT
Completed No phase listed Observational

Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings

NCT06093490
View directory record Official record
Conditions
Absence Epilepsy, Childhood, Absence Seizures, Absence Epilepsy, Epilepsy in Children, Staring, Seizures
Interventions
Eysz Hyperventilation Recorder
Device
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
65 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 11:23 AM EDT
Recruiting Phase 3 Interventional

Ketogenic Diet for New-Onset Absence Epilepsy

NCT04274179
View directory record Official record
Conditions
Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence
Interventions
Modified Atkins Diet, Absence epilepsy medications
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 12 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118949
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Alabaster, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

NCT06769659
View directory record Official record
Conditions
Epilepsy, Generalized, Epilepsy, Absence
Interventions
NPT 2042, Placebo
Drug · Other
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

CX-8998 for Absence Seizures

NCT03406702
View directory record Official record
Conditions
Epilepsy
Interventions
CX-8998
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
16 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Little Rock, Arkansas • Tampa, Florida • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Not applicable Interventional

ECV - Epihunter Clinical Validation

NCT04615442
View directory record Official record
Conditions
Absence Seizures, Absence Epilepsy
Interventions
Epihunter
Device
Lead sponsor
Epihunter NV
Industry
Eligibility
4 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Not applicable Interventional

A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy

NCT00361010
View directory record Official record
Conditions
Epilepsy, Childhood Absence Epilepsy, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
4 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Jul 21, 2026, 11:23 AM EDT
Completed No phase listed Observational

Detecting Absence Seizures Using Eye Tracking

NCT04439656
View directory record Official record
Conditions
Epilepsy, Generalized, Absence Epilepsy, Absence Seizures, Seizures, Seizure Disorder
Interventions
Eye movement analysis
Diagnostic Test
Lead sponsor
Rachel Kuperman
Industry
Eligibility
4 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Orange, California • San Diego, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 21, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118962
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 11:23 AM EDT